PMID- 37839018
OWN - NLM
STAT- MEDLINE
DCOM- 20231127
LR  - 20231127
IS  - 1523-5378 (Electronic)
IS  - 1083-4389 (Linking)
VI  - 28
IP  - 6
DP  - 2023 Dec
TI  - Efficacy and safety of minocycline quadruple therapy for Helicobacter pylori 
      eradication: A meta-analysis of RCTs.
PG  - e13022
LID - 10.1111/hel.13022 [doi]
AB  - BACKGROUND: The effective regimen is lacking in areas with high antibiotic 
      resistance and tetracycline unavailable. Whether minocycline can replace 
      tetracycline for Helicobacter pylori eradication is unknown. This meta-analysis 
      compared and summarized the efficacy and safety profiles of H. pylori quadruple 
      regimens with and without minocycline. MATERIALS AND METHODS: We conducted a 
      literature search for regimens including minocycline quadruple therapy for 
      H. pylori eradication and adverse events (AEs). Controls were patients undergoing 
      any other treatment without minocycline. Searches were performed up to July 20, 
      2023, using PubMed and the Cochrane library. RESULTS: A total of five randomized 
      controlled clinical trials with 2004 patients were included in this 
      meta-analysis. The H. pylori eradication rate of minocycline quadruple therapy 
      was similar with that of control therapy (83.8% vs. 80.6%, OR 1.25, 95% CI 
      [0.99-1.57], I(2)  = 0%, p = 0.06) in ITT analysis. When treatment regimens with 
      minocycline were compared only with treatment regimens with tetracycline, no 
      significant difference was found in eradication rate:85.5% vs. 85.5%, OR 1.00, 
      95% CI 0.67-1.47, p = 1.00. But when treatment regimens with minocycline were 
      compared with treatment regimens without tetracycline, the former was 
      significantly superiority to the latter (82.7% vs. 77.2%; OR, 1.40, 95% CI 
      1.06-1.87, p = 0.02). The incidence of AEs in the quadruple therapy with 
      minocycline group was similar with the control group (35.9% vs. 38.8%, OR 0.88, 
      95% CI [0.73-1.06], I(2)  = 13%, p = 0.17). CONCLUSIONS: We demonstrated the 
      H. pylori eradication effect of minocycline quadruple therapy, and it might be an 
      optional therapy. The safety of regimens containing minocycline was relatively 
      satisfactory.
CI  - (c) 2023 John Wiley & Sons Ltd.
FAU - Gao, Wenwen
AU  - Gao W
AD  - Department of Pharmacy, Central Hospital Affiliated to Shandong First Medical 
      University, Jinan, China.
FAU - Zhu, Mingliang
AU  - Zhu M
AD  - Department of Pharmacy, The Affiliated Hospital of Shandong University of 
      Traditional Chinese Medicine, Jinan, China.
FAU - Yin, Yanhui
AU  - Yin Y
AD  - Department of Pharmacy, Central Hospital Affiliated to Shandong First Medical 
      University, Jinan, China.
FAU - Zhang, Xiang
AU  - Zhang X
AD  - Department of Pharmacy, Central Hospital Affiliated to Shandong First Medical 
      University, Jinan, China.
FAU - Wang, Lu
AU  - Wang L
AD  - Department of Pharmacy, Central Hospital Affiliated to Shandong First Medical 
      University, Jinan, China.
LA  - eng
GR  - Jinan Science and Technology Bureau (#202134050)/
GR  - Jinan Science and Technology Development Program of Health Commission 
      (2022-2-04)/
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20231015
PL  - England
TA  - Helicobacter
JT  - Helicobacter
JID - 9605411
RN  - FYY3R43WGO (Minocycline)
RN  - 0 (Anti-Bacterial Agents)
RN  - F8VB5M810T (Tetracycline)
RN  - U015TT5I8H (Bismuth)
RN  - 804826J2HU (Amoxicillin)
SB  - IM
MH  - Humans
MH  - Minocycline/adverse effects
MH  - *Helicobacter pylori
MH  - *Helicobacter Infections/drug therapy
MH  - Drug Therapy, Combination
MH  - Anti-Bacterial Agents/adverse effects
MH  - Tetracycline/adverse effects
MH  - Bismuth/therapeutic use
MH  - Treatment Outcome
MH  - Amoxicillin/therapeutic use
MH  - Randomized Controlled Trials as Topic
OTO - NOTNLM
OT  - helicobacter pylori
OT  - eradication rate
OT  - meta-analysis
OT  - minocycline
OT  - quadruple therapy
EDAT- 2023/10/15 18:42
MHDA- 2023/11/27 12:44
CRDT- 2023/10/15 15:10
PHST- 2023/08/22 00:00 [revised]
PHST- 2023/08/21 00:00 [received]
PHST- 2023/09/14 00:00 [accepted]
PHST- 2023/11/27 12:44 [medline]
PHST- 2023/10/15 18:42 [pubmed]
PHST- 2023/10/15 15:10 [entrez]
AID - 10.1111/hel.13022 [doi]
PST - ppublish
SO  - Helicobacter. 2023 Dec;28(6):e13022. doi: 10.1111/hel.13022. Epub 2023 Oct 15.